Skip to main content
main-content

Zeitschrift

Journal of Translational Medicine

Journal of Translational Medicine 1/2014

Sonderheft 1/2014

Melanoma Bridge 2013: Poster and Oral Presentations

Inhaltsverzeichnis ( 26 Artikel )

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Revealing cancer initiating cells in metastatic melanomas by harnessing the host′s anti tumor humoral immune mechanisms

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Regulation of melanoma initiating cells by Hedgehog signaling and SOX2

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600 - mutated melanoma (BRIM7)

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase 1 production

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Harnessing host innate immunity may combat acquired resistance to BRAFi

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

A novel approach to target metastases of melanoma cells in an organ-selective manner

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

UV exposure and melanoma prognostic factors : results from Clinical National Melanoma Registry (CNMR)

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Psychological features in lower risk melanoma: an analysis on 204 patients

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Natural immunomodulator preimplantation factor PIF affected cancer growth in malignant melanomas

01.05.2014 | Oral presentation | Sonderheft 1/2014 Open Access

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

In vivo targeting of cutaneous melanoma using an MSH-engineered human protein cage bearing fluorophore and MRI tracers

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Barasertib: a novel approach for the treatment of metastatic melanoma

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status

Aktuelle Ausgaben